Antidepressants - Selective Serotonin Reuptake Inhibitors Drug Quantity Management Policy - Per Rx
Defines drug quantity limits and coverage determination process for selective serotonin reuptake inhibitors (SSRIs) for Cigna-administered health benefit plans; applies to providers prescribing listed SSRI products and to pharmacy claim adjudication at point of service.
Brand Sarafem 10 mg and 20 mg tablets removed from the policy as obsolete.
Generic vilazodone tablets (10 mg, 20 mg, 40 mg) added to the policy with existing Viibryd quantity limits and override criteria applied.
Notes regarding how dosing can be administered were removed for multiple listed products (e.g., citalopram, escitalopram, fluoxetine, sertraline, trintellix, vilazodone).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.